FDA accepted the New Drug Application for repotrectinib, a next-generation tyrosine kinase inhibitor, for the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer based on results from the phase I/II TRIDENT-1 trial. FDA granted the application priority review and assigned a Prescription Drug User Fee Act goal date of November 27.
Today’s critical shortage of cisplatin and carboplatin occurred because manufacturers failed to invest in enhancing production capacity, Richard Pazdur, director of the FDA Oncology Center of Excellence and acting director of the Office of Oncologic Diseases, said to The Cancer Letter.
FDA granted accelerated approval to Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
FDA granted PYX-201 Orphan Drug Designation in pancreatic cancer.
The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic castration-resistant prostate cancer patients whose tumors have a BRCA mutation.
Can data from one CAR T-cell therapy be used to inform FDA’s review of other CAR T products?
CAR T-cell therapies have been used to treat cancer patients since 2011, but infection-related adverse events remain a significant hurdle. Often, fever is one of the earliest warning signs of clinical deterioration and a potentially life-threatening condition.
FDA approved the Premarket Approval application for xT CDx, a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
FDA released a draft guidance, “Decentralized Clinical Trials for Drugs, Biological Products, and Devices” to support the use of decentralized clinical trials for drugs, biologics and devices, where some or all the trial-related activities occur at locations other than traditional clinical trial sites.
FDA accepted the supplemental Biologics License Application sBLA and the European Medicines Agency has validated the Type II Variation Application for Reblozyl (luspatercept-aamt) to expand its current indication to include treatment of anemia without previous use of erythropoiesis-stimulating agents in adult patients with very low- to intermediate-risk myelodysplastic syndromes who may require red blood cell transfusions.
